Resveratrol in Type2 Diabetes and Obesity
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01158417|
Recruitment Status : Terminated (FDA clinical hold requiring IND submission, product not available in the market anymore)
First Posted : July 8, 2010
Last Update Posted : November 9, 2022
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Obesity Insulin Resistance||Drug: Placebo Drug: Resveratrol 40 mg oral three times a day Drug: Resveratrol 500 mg oral once daily.||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||15 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Effect of Resveratrol on Insulin Resistance and Inflammatory Mediators in Obese and Type 2 Diabetic Subjects|
|Actual Study Start Date :||December 2008|
|Actual Primary Completion Date :||July 8, 2012|
|Actual Study Completion Date :||July 8, 2012|
Placebo Comparator: Placebo
Experimental: Resveratrol 40 mg oral three times a day
Drug: Resveratrol 40 mg oral three times a day
Other Name: Resveratrol 40mg
Experimental: resveratrol 500 mg oral once daily.
Drug: Resveratrol 500 mg oral once daily.
Resveratrol 500 mg oral once daily.
Other Name: Resveratrol 500 mg
- NF-Kb [ Time Frame: 12 weeks ]To investigate the effect of resveratrol on ROS generation and the pro-inflammatory transcription factor NF-kB
- GLP-1 [ Time Frame: 12 weeks ]To see whether Resveratrol leads to a greater stimulation of the incretin system and secretion/release of GIP and GLP-1 when compared to that following placebo
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01158417
|United States, New York|
|Williamsville, New York, United States, 14221|
|Principal Investigator:||Paresh Dandona, MD||Kaleida Health|